Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about JOUNCE THERAPEUTICS, INC.
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of D..
PU
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/15Jounce Therapeutics, Inc. Announces Board Changes
CI
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14JOUNCE THERAPEUTICS : Raymond James Upgrades Jounce Therapeutics to Outperform F..
MT
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
08/05Jounce Therapeutics Reports Second Quarter 2021 Financial Results
GL
08/05Jounce Therapeutics, Inc. Reports Earnings Results for the Second Quarter End..
CI
07/29Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Hos..
GL
07/07JOUNCE THERAPEUTICS : to Participate in William Blair's Biotech Focus Conference
AQ
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Value-Defen..
CI
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Defensive I..
CI
06/23Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Ex..
GL
06/16Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
GL
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
06/15Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
06/15JOUNCE THERAPEUTICS : Set for $25 Million Milestone Payment from Gilead After In..
MT
06/15Wall Street Sees Muted Open Amid Data Deluge
MT
06/15GILEAD SCIENCES : Jounce Therapeutics Achieves First Milestone in Exclusive Lice..
AQ
06/15Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement w..
CI
06/15Jounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
DJ
06/14Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Huma..
GL
06/04Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELE..
GL
05/28JOUNCE THERAPEUTICS : JNCE) Insider Makes Significant Share Sale
MT
05/27INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Jounce Therapeutics
MT
05/08Certain Common Stock of Jounce Therapeutics, Inc. are subject to a Lock-Up Ag..
CI
05/08Certain Stock Options of Jounce Therapeutics, Inc. are subject to a Lock-Up A..
CI
05/08Certain Restricted Stock Units of Jounce Therapeutics, Inc. are subject to a ..
CI
05/04JOUNCE THERAPEUTICS : Reports Narrower Q1 Loss
MT
05/04JOUNCE THERAPEUTICS : Enrollment on track in both the Phase 1 INNATE trial of JT..
PU
05/04Jounce Therapeutics Reports First Quarter 2021 Financial Results
GL
05/04Jounce Therapeutics, Inc. Reports Earnings Results for the First Quarter Ende..
CI
04/28Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNAT..
GL
04/28Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 Innat..
CI
04/27Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host..
GL
04/12Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific ..
GL
04/12Jounce Therapeutics, Inc. Appoints Dmitri Wiederschain as Chief Scientific Of..
CI
04/10Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at..
GL
04/10Jounce Therapeutics, Inc. Presents Preclinical Data from JTX-8064/LILRB2 Prog..
CI
03/15JOUNCE THERAPEUTICS : Piper Sandler Starts Jounce Therapeutics at Overweight Wit..
MT
03/12JOUNCE THERAPEUTICS : Closes Common Stock Offering, Raises $64.7 Million in Gros..
MT
03/12Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of..
GL
03/11SECTOR UPDATE : Health Care Stocks Carried Higher By Biotech Companies
MT
03/11JOUNCE THERAPEUTICS : Rises on Plan to Present Preclinical JTX-8064 Data at Canc..
MT
03/11JOUNCE THERAPEUTICS : to Present Preclinical Data from JTX-8064 Program at the 2..
AQ
03/10Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the ..
GL
03/10JOUNCE THERAPEUTICS : Prices Public Offering at $11.25/Share, Expects to Raise $..
MT
03/09Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Co..
GL
03/09JOUNCE THERAPEUTICS : Plans Share Offering; Stock Dives 7% After Hours
MT
03/09Jounce Therapeutics Announces Proposed Offering of Common Stock
GL
02/25Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Resul..
GL
02/25Jounce Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter End..
CI
02/23Jounce Therapeutics to Present at Upcoming Investor Conferences in March
GL
02/18Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial R..
GL
02/15JOUNCE THERAPEUTICS : Appoints Luisa Salter-Cid, Ph.D., to its Board of Director..
AQ
02/12Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directo..
GL
02/12Jounce Therapeutics Appoints Luisa Salter-Cid, to Its Board of Directors
CI
01/14JOUNCE THERAPEUTICS : Announces Initiation of Phase 1 INNATE Study of JTX-8064 M..
AQ
01/13JOUNCE THERAPEUTICS : Initiates Phase 1 Study of JTX-8064 to Treat Solid Tumors
MT
01/13Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 ..
GL
01/13Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 ..
CI
01/11JOUNCE THERAPEUTICS : to Present at Upcoming Investor Conferences in January
AQ
01/11INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Jounce Therapeutics
MT
01/08Jounce Therapeutics to Present at Upcoming Investor Conferences in January
GL
2020JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) added to NASDAQ Biotechnology Index
CI
2020JOUNCE THERAPEUTICS : to be Added to NASDAQ Biotechnology Index
MT
2020JOUNCE THERAPEUTICS : Added to NASDAQ Biotechnology Index
AQ
2020JOUNCE THERAPEUTICS : HC Wainwright Starts Jounce Therapeutics at Buy With $11 P..
MT
2020JOUNCE THERAPEUTICS : to Participate in a Fireside Chat at the Piper Sandler 32n..
AQ
2020Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32..
GL
2020JOUNCE THERAPEUTICS : to Participate in a Fireside Chat at the Piper Sandler 32n..
AQ
2020INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Jounce Therapeutics
MT
2020INSIDER TRENDS : Jounce Therapeutics Insider Extends 90-Day Selling Trend
MT
2020JOUNCE THERAPEUTICS : Receives Study May Proceed Letter from US FDA to Initiate ..
AQ
2020JOUNCE THERAPEUTICS : Receives FDA Approval to Begin Phase 1 Trial of JTX-8064
MT
1  2  3Next
Upcoming event on JOUNCE THERAPEUTICS, INC.
09/29/21